Open beta · everything is free with an account while we build. Founding accounts get preferred pricing when paid plans arrive. Create yours →
KT

KIMBERLEE TRZECIAK

Registered · LDAActive

Background

Career
Washington, DC · current
Government experience
FDA. Dep. Commissioner; 8/23-1/25. Assoc. Commissioner Leg. Affairs; 2/2022-08/2023. House Com. Energy & Commerce: Chief Health Advisor
2/22-4/19. Sen. Health Policy Advisor, 3/19-3/15. Rep. John D. Dingell - LD, 05/13-07/11. Sen. LA, 7/11-08/09, LA
Covered official positions, as disclosed on federal filings

The past 12 months

Clients
21
past 12 months
Filings
23
past 12 months
Agencies contacted
HOUSE OF REPRESENTATIVESSENATEHealth & Human Services, Dept of (HHS)Centers For Medicare and Medicaid Services (CMS)Food & Drug Administration (FDA)Agriculture, Dept of (USDA)Federal Aviation Administration (FAA)Health Resources & Services Administration (HRSA)Transportation, Dept of (DOT)

Specific issues

Infant Formula Safety, Nutrition, Innovation, and Manufacturing.
Health Issues · 2026 Q1
Regulation of and payment of over-the-counter drugs (OTC), including OTC switches.
Health Issues · 2026 Q1
Issues surrounding improvements to clinical research capabilities and modernization of research methods.
Food Industry (safety, labeling, etc.) · 2026 Q1
Issues surrounding improvements to clinical research capabilities and modernization of research methods. Issues related to preclinical testing safety assessments, including New Approach Methodologies and virtual control groups
Health Issues · 2026 Q1
Community Health Centers Funding, PACE Program
Health Issues · 2026 Q1
Community Health Centers Funding, PACE Program. Issues relating to 340B drug pricing program.
Medicare/Medicaid · 2026 Q1

Clients

2026 · 1 filing
$██,███ / qtrFree in beta
2026 · 1 filing
$██,███ / qtrFree in beta
$██,███ / qtrFree in beta
2026 · 2 filings
$██,███ / qtrFree in beta
2026 · 1 filing
$██,███ / qtrFree in beta
2026 · 1 filing
$██,███ / qtrFree in beta
2026 · 1 filing
$██,███ / qtrFree in beta
$██,███ / qtrFree in beta
2026 · 1 filing
$██,███ / qtrFree in beta
2026 · 1 filing
$██,███ / qtrFree in beta
2026 · 1 filing
$██,███ / qtrFree in beta
2026 · 1 filing
$██,███ / qtrFree in beta
2026 · 1 filing
$██,███ / qtrFree in beta
2026 · 1 filing
$██,███ / qtrFree in beta
2026 · 1 filing
$██,███ / qtrFree in beta
$██,███ / qtrFree in beta
2026 · 1 filing
$██,███ / qtrFree in beta
2026 · 1 filing
$██,███ / qtrFree in beta
2026 · 1 filing
$██,███ / qtrFree in beta
2026 · 1 filing
$██,███ / qtrFree in beta
2026 · 1 filing
$██,███ / qtrFree in beta

Sources

This profile is built from the public record: filings in the U.S. Senate Lobbying Disclosure Act system. lda.senate.gov ↗

Recent filings14
2026 Q1
CIGNA
Q1lda.gov →
2026 Q1
BAUSCH HEALTH
Q1lda.gov →
2026 Q1
GOODRX, INC
Q1lda.gov →
2026 Q1
BYHEART, INC.
Q1lda.gov →
2026 Q1
AMERICAN CHIROPRACTIC ASSOCIATION, INC.
Q1lda.gov →
2026 Q1
CLENE NANOMEDICINE
Q1lda.gov →
2026 Q1
ONE HEALTH PARTNERS
Q1lda.gov →
2026 Q1
CHARLES RIVER LABORATORIES INTERNATIONAL, INC
Q1lda.gov →
2026 Q1
HUMACYTE
Q1lda.gov →
2026 Q1
CVS PREVIOUSLY AETNA
Q1lda.gov →
2026 Q1
GLOBAL MEDICAL RESPONSE
Q1lda.gov →
2026 Q1
OCULAR THREPEUTIX
Q1lda.gov →
2026 Q1
BETTER MEDICARE ALLIANCE
Q1lda.gov →
2026 Q1
HALEON US HOLDINGS, LLC
Q1lda.gov →